ChemPartner PharmaTechLtd (300149) 주식 개요켐파트너 파마텍은 전 세계적으로 미생물 영양 및 헬스케어 사업을 영위하고 있습니다. 자세히 보기300149 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성6/6배당0/6위험 분석지난 5년간 매년 수익이 23.1% 감소했습니다.지난 3개월 동안 주가 변동성이 CN 시장과 비교해 높았습니다.모든 위험 점검 보기300149 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW493,048 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG493,048 investors already sharing narrativesYour Fair ValueCN¥Current PriceCN¥10.18143.5% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-914m2b2016201920222025202620282031Revenue CN¥615.9mEarnings CN¥110.6mAdvancedSet Fair ValueView all narrativesChemPartner PharmaTech Co.,Ltd. 경쟁사HOB Biotech GroupLtdSymbol: SHSE:688656Market cap: CN¥5.2bHangzhou Biotest BiotechLtdSymbol: SHSE:688767Market cap: CN¥5.2bChengdu Kanghua Biological ProductsSymbol: SZSE:300841Market cap: CN¥6.0bWuhan Hiteck Biological PharmaLtdSymbol: SZSE:300683Market cap: CN¥3.6b가격 이력 및 성과ChemPartner PharmaTechLtd 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CN¥10.1852주 최고가CN¥15.2852주 최저가CN¥7.22베타0.761개월 변동33.07%3개월 변동-5.83%1년 변동-11.56%3년 변동27.57%5년 변동-30.18%IPO 이후 변동-29.99%최근 뉴스 및 업데이트Buy Or Sell Opportunity • Jul 15Now 41% overvaluedOver the last 90 days, the stock has fallen 9.0% to CN¥10.39. The fair value is estimated to be CN¥7.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.공고 • Jun 30ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026Buy Or Sell Opportunity • Jun 29Now 36% overvaluedOver the last 90 days, the stock has fallen 4.7% to CN¥9.86. The fair value is estimated to be CN¥7.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.공고 • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026, at 13:30 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026더 많은 업데이트 보기Recent updatesBuy Or Sell Opportunity • Jul 15Now 41% overvaluedOver the last 90 days, the stock has fallen 9.0% to CN¥10.39. The fair value is estimated to be CN¥7.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.공고 • Jun 30ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026Buy Or Sell Opportunity • Jun 29Now 36% overvaluedOver the last 90 days, the stock has fallen 4.7% to CN¥9.86. The fair value is estimated to be CN¥7.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.공고 • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026, at 13:30 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026공고 • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026공고 • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2025 Results on Oct 30, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025공고 • Jul 02ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2025 Results on Aug 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2025 results on Aug 29, 2025공고 • May 22Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd.Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. agreed to acquire 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. for approximately CNY 130 million on March 31, 2025. The consideration consist of CNY 5.064 per ChemPartner PharmaTech Co.,Ltd. share. Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. on May 20, 2025.공고 • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time.공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025공고 • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025공고 • Nov 16ChemPartner PharmaTech Co.,Ltd. Approves the Election of DirectorsChemPartner PharmaTech Co.,Ltd. held its 2nd Extraordinary General Meeting of 2024 on 14 November 2024, during which the following proposal(s) was/were approved the election of Chen Wanglong as non-independent director and Zhang Xuemei as independent director.공고 • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024Reported Earnings • Aug 30Second quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.011 profit in 2Q 2023)Second quarter 2024 results: CN¥0.076 loss per share (down from CN¥0.011 profit in 2Q 2023). Revenue: CN¥230.6m (down 20% from 2Q 2023). Net loss: CN¥37.4m (down CN¥44.2m from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance.공고 • Jun 29ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2024 results on Aug 30, 2024공고 • Apr 28Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024, at 14:00 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China Agenda: To consider 2023 work report of the board of directors; to consider 2023 annual accounts report; to consider 2023 annual report and its summary; to consider 2023 profit distribution plan; to consider Application for comprehensive credit line to banks and other financial institutions and provision of guarantee; to consider Shareholder return plan for the next three years from 2024 to 2026; to consider Authorization to the board to handle matters regarding the share offering to specific parties via a simplified procedure; to consider Change of the Company's business scope and amendments to the Company's articles of association; to consider 2023 work report of the supervisory committee; and to consider other business matters.Reported Earnings • Apr 27First quarter 2024 earnings released: CN¥0.051 loss per share (vs CN¥0.057 loss in 1Q 2023)First quarter 2024 results: CN¥0.051 loss per share (improved from CN¥0.057 loss in 1Q 2023). Revenue: CN¥234.6m (down 13% from 1Q 2023). Net loss: CN¥25.5m (loss narrowed 11% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance.New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).공고 • Mar 30Chempartner Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Chempartner Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024공고 • Dec 30Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024Chempartner Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024Reported Earnings • Oct 25Third quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.13 profit in 3Q 2022)Third quarter 2023 results: CN¥0.048 loss per share (down from CN¥0.13 profit in 3Q 2022). Revenue: CN¥288.7m (down 16% from 3Q 2022). Net loss: CN¥19.4m (down 129% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥1.90 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.011 (down from CN¥1.90 in 2Q 2022). Revenue: CN¥288.8m (down 3.9% from 2Q 2022). Net income: CN¥6.79m (down 99% from 2Q 2022). Profit margin: 2.4% (down from 315% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Aug 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥7.25, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 36x in the Biotechs industry in China. Total loss to shareholders of 65% over the past three years.New Risk • Aug 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥9.47, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 40x in the Biotechs industry in China. Total loss to shareholders of 58% over the past three years.Reported Earnings • Apr 28First quarter 2023 earnings released: CN¥0.057 loss per share (vs CN¥0.019 profit in 1Q 2022)First quarter 2023 results: CN¥0.057 loss per share (down from CN¥0.019 profit in 1Q 2022). Revenue: CN¥268.7m (down 31% from 1Q 2022). Net loss: CN¥28.6m (down 402% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Supervisor Jiahui Qi is the most experienced director on the board, commencing their role in 2018. Independent Director Ji Guo Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2021). Revenue: CN¥345.3m (down 17% from 3Q 2021). Net income: CN¥66.8m (up CN¥57.1m from 3Q 2021). Profit margin: 19% (up from 2.3% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: CN¥1.90 (vs CN¥0.007 in 2Q 2021)Second quarter 2022 results: EPS: CN¥1.90 (up from CN¥0.007 in 2Q 2021). Revenue: CN¥300.6m (down 34% from 2Q 2021). Net income: CN¥947.1m (up CN¥943.6m from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.Reported Earnings • May 02First quarter 2022 earnings released: EPS: CN¥0.019 (vs CN¥0.003 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.019 (up from CN¥0.003 in 1Q 2021). Revenue: CN¥386.3m (flat on 1Q 2021). Net income: CN¥9.47m (up 480% from 1Q 2021). Profit margin: 2.5% (up from 0.4% in 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Member of the Supervisory Board Hai Zhang was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to CN¥12.10, the stock trades at a trailing P/E ratio of 70.1x. Average trailing P/E is 44x in the Biotechs industry in China. Total loss to shareholders of 22% over the past three years.Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.007 (vs CN¥0.11 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥455.7m (up 16% from 2Q 2020). Net income: CN¥3.51m (down 94% from 2Q 2020). Profit margin: 0.8% (down from 14% in 2Q 2020).Valuation Update With 7 Day Price Move • May 15Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥16.39, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 47x in the Biotechs industry in China. Total returns to shareholders of 41% over the past year.Reported Earnings • Apr 30First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.028 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥389.7m (up 40% from 1Q 2020). Net income: CN¥1.63m (up CN¥15.8m from 1Q 2020). Profit margin: 0.4% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue.Is New 90 Day High Low • Mar 16New 90-day low: CN¥12.64The company is down 27% from a price of CN¥17.30 on 16 December 2020. Underperformed the Chinese market, which is down 2.0% over the last 90 days. Lagged the Biotechs industry, which is down 6.0% over the same period.Is New 90 Day High Low • Jan 28New 90-day low: CN¥12.66The company is down 36% from its price of CN¥19.93 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.53 per share.Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CN¥14.46, the stock is trading at a trailing P/E ratio of 51.2x, down from the previous P/E ratio of 60.5x. This compares to an average P/E of 63x in the Biotechs industry in China. Total returns to shareholders over the past year are 10%.Is New 90 Day High Low • Dec 24New 90-day low: CN¥14.46The company is down 31% from its price of CN¥20.99 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.53 per share.Is New 90 Day High Low • Nov 12New 90-day low: CN¥18.29The company is down 4.0% from its price of CN¥19.06 on 14 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥13.18 per share.Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥141.1m, up 8.5% from the prior year. Total revenue was CN¥1.44b over the last 12 months, up 8.5% from the prior year.주주 수익률300149CN BiotechsCN 시장7D17.8%1.9%-6.2%1Y-11.6%-23.8%8.3%전체 주주 수익률 보기수익률 대 산업: 300149은 지난 1년 동안 -23.8%의 수익을 기록한 CN Biotechs 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: 300149은 지난 1년 동안 8.3%를 기록한 CN 시장보다 저조한 성과를 냈습니다.주가 변동성Is 300149's price volatile compared to industry and market?300149 volatility300149 Average Weekly Movement11.7%Biotechs Industry Average Movement7.1%Market Average Movement7.3%10% most volatile stocks in CN Market12.1%10% least volatile stocks in CN Market4.3%안정적인 주가: 300149의 주가는 지난 3개월 동안 CN 시장보다 변동성이 컸습니다.시간에 따른 변동성: 300149의 주간 변동성(12%)은 지난 1년 동안 안정적이었지만 CN 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트20001,771Swee Lian Woowww.cppt.com.cn켐파트너 파마텍은 전 세계적으로 미생물 영양 및 헬스케어 사업에 종사하고 있습니다. 이 회사는 미생물 영양 및 의료 사업과 제약 연구 개발 서비스 및 생산 아웃소싱 사업의 두 가지 부문으로 운영됩니다. 프리바이오틱스 제품과 미생물학적 의료 서비스를 제공합니다.더 보기ChemPartner PharmaTech Co.,Ltd. 기초 지표 요약ChemPartner PharmaTechLtd의 순이익과 매출은 시가총액과 어떻게 비교됩니까?300149 기초 통계시가총액CN¥5.07b순이익 (TTM)-CN¥11.39m매출 (TTM)CN¥1.14b4.4x주가매출비율(P/S)-445.2x주가수익비율(P/E)300149는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표300149 손익계산서 (TTM)매출CN¥1.14b매출원가CN¥826.09m총이익CN¥314.06m기타 비용CN¥325.44m순이익-CN¥11.39m최근 보고된 실적Mar 31, 2026다음 실적 발표일Aug 29, 2026주당순이익(EPS)-0.023총이익률27.55%순이익률-1.00%부채/자본 비율7.3%300149의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/20 14:39종가2026/07/20 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ChemPartner PharmaTech Co.,Ltd.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullCMB International Securities LimitedXiao Bao LiuEverbright Securities Co. Ltd.Yun ZHANGHuatai Research
Buy Or Sell Opportunity • Jul 15Now 41% overvaluedOver the last 90 days, the stock has fallen 9.0% to CN¥10.39. The fair value is estimated to be CN¥7.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.
공고 • Jun 30ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026
Buy Or Sell Opportunity • Jun 29Now 36% overvaluedOver the last 90 days, the stock has fallen 4.7% to CN¥9.86. The fair value is estimated to be CN¥7.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
공고 • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026, at 13:30 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China
공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
Buy Or Sell Opportunity • Jul 15Now 41% overvaluedOver the last 90 days, the stock has fallen 9.0% to CN¥10.39. The fair value is estimated to be CN¥7.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.
공고 • Jun 30ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026
Buy Or Sell Opportunity • Jun 29Now 36% overvaluedOver the last 90 days, the stock has fallen 4.7% to CN¥9.86. The fair value is estimated to be CN¥7.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
공고 • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026, at 13:30 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China
공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
공고 • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026
공고 • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2025 Results on Oct 30, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025
공고 • Jul 02ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2025 Results on Aug 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
공고 • May 22Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd.Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. agreed to acquire 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. for approximately CNY 130 million on March 31, 2025. The consideration consist of CNY 5.064 per ChemPartner PharmaTech Co.,Ltd. share. Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. on May 20, 2025.
공고 • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time.
공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
공고 • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
공고 • Nov 16ChemPartner PharmaTech Co.,Ltd. Approves the Election of DirectorsChemPartner PharmaTech Co.,Ltd. held its 2nd Extraordinary General Meeting of 2024 on 14 November 2024, during which the following proposal(s) was/were approved the election of Chen Wanglong as non-independent director and Zhang Xuemei as independent director.
공고 • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024
Reported Earnings • Aug 30Second quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.011 profit in 2Q 2023)Second quarter 2024 results: CN¥0.076 loss per share (down from CN¥0.011 profit in 2Q 2023). Revenue: CN¥230.6m (down 20% from 2Q 2023). Net loss: CN¥37.4m (down CN¥44.2m from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance.
공고 • Jun 29ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2024 results on Aug 30, 2024
공고 • Apr 28Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024, at 14:00 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China Agenda: To consider 2023 work report of the board of directors; to consider 2023 annual accounts report; to consider 2023 annual report and its summary; to consider 2023 profit distribution plan; to consider Application for comprehensive credit line to banks and other financial institutions and provision of guarantee; to consider Shareholder return plan for the next three years from 2024 to 2026; to consider Authorization to the board to handle matters regarding the share offering to specific parties via a simplified procedure; to consider Change of the Company's business scope and amendments to the Company's articles of association; to consider 2023 work report of the supervisory committee; and to consider other business matters.
Reported Earnings • Apr 27First quarter 2024 earnings released: CN¥0.051 loss per share (vs CN¥0.057 loss in 1Q 2023)First quarter 2024 results: CN¥0.051 loss per share (improved from CN¥0.057 loss in 1Q 2023). Revenue: CN¥234.6m (down 13% from 1Q 2023). Net loss: CN¥25.5m (loss narrowed 11% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance.
New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
공고 • Mar 30Chempartner Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Chempartner Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
공고 • Dec 30Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024Chempartner Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024
Reported Earnings • Oct 25Third quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.13 profit in 3Q 2022)Third quarter 2023 results: CN¥0.048 loss per share (down from CN¥0.13 profit in 3Q 2022). Revenue: CN¥288.7m (down 16% from 3Q 2022). Net loss: CN¥19.4m (down 129% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥1.90 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.011 (down from CN¥1.90 in 2Q 2022). Revenue: CN¥288.8m (down 3.9% from 2Q 2022). Net income: CN¥6.79m (down 99% from 2Q 2022). Profit margin: 2.4% (down from 315% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥7.25, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 36x in the Biotechs industry in China. Total loss to shareholders of 65% over the past three years.
New Risk • Aug 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥9.47, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 40x in the Biotechs industry in China. Total loss to shareholders of 58% over the past three years.
Reported Earnings • Apr 28First quarter 2023 earnings released: CN¥0.057 loss per share (vs CN¥0.019 profit in 1Q 2022)First quarter 2023 results: CN¥0.057 loss per share (down from CN¥0.019 profit in 1Q 2022). Revenue: CN¥268.7m (down 31% from 1Q 2022). Net loss: CN¥28.6m (down 402% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Supervisor Jiahui Qi is the most experienced director on the board, commencing their role in 2018. Independent Director Ji Guo Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2021). Revenue: CN¥345.3m (down 17% from 3Q 2021). Net income: CN¥66.8m (up CN¥57.1m from 3Q 2021). Profit margin: 19% (up from 2.3% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: CN¥1.90 (vs CN¥0.007 in 2Q 2021)Second quarter 2022 results: EPS: CN¥1.90 (up from CN¥0.007 in 2Q 2021). Revenue: CN¥300.6m (down 34% from 2Q 2021). Net income: CN¥947.1m (up CN¥943.6m from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 02First quarter 2022 earnings released: EPS: CN¥0.019 (vs CN¥0.003 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.019 (up from CN¥0.003 in 1Q 2021). Revenue: CN¥386.3m (flat on 1Q 2021). Net income: CN¥9.47m (up 480% from 1Q 2021). Profit margin: 2.5% (up from 0.4% in 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Member of the Supervisory Board Hai Zhang was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to CN¥12.10, the stock trades at a trailing P/E ratio of 70.1x. Average trailing P/E is 44x in the Biotechs industry in China. Total loss to shareholders of 22% over the past three years.
Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.007 (vs CN¥0.11 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥455.7m (up 16% from 2Q 2020). Net income: CN¥3.51m (down 94% from 2Q 2020). Profit margin: 0.8% (down from 14% in 2Q 2020).
Valuation Update With 7 Day Price Move • May 15Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥16.39, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 47x in the Biotechs industry in China. Total returns to shareholders of 41% over the past year.
Reported Earnings • Apr 30First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.028 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥389.7m (up 40% from 1Q 2020). Net income: CN¥1.63m (up CN¥15.8m from 1Q 2020). Profit margin: 0.4% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue.
Is New 90 Day High Low • Mar 16New 90-day low: CN¥12.64The company is down 27% from a price of CN¥17.30 on 16 December 2020. Underperformed the Chinese market, which is down 2.0% over the last 90 days. Lagged the Biotechs industry, which is down 6.0% over the same period.
Is New 90 Day High Low • Jan 28New 90-day low: CN¥12.66The company is down 36% from its price of CN¥19.93 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.53 per share.
Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CN¥14.46, the stock is trading at a trailing P/E ratio of 51.2x, down from the previous P/E ratio of 60.5x. This compares to an average P/E of 63x in the Biotechs industry in China. Total returns to shareholders over the past year are 10%.
Is New 90 Day High Low • Dec 24New 90-day low: CN¥14.46The company is down 31% from its price of CN¥20.99 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.53 per share.
Is New 90 Day High Low • Nov 12New 90-day low: CN¥18.29The company is down 4.0% from its price of CN¥19.06 on 14 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥13.18 per share.
Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥141.1m, up 8.5% from the prior year. Total revenue was CN¥1.44b over the last 12 months, up 8.5% from the prior year.
